Peptides derived from human PCSK9 catalytic domain and uses thereof for promoting LDL-R activity
The present invention provides compositions comprising an isolated or purified therapeutically effective hPCSK9 polypeptide derived from the hPCSK9 catalytic domain, and their use in methods of treating hypercholesterolemia.
1. The isolated or purified therapeutically effective hPCSK9 polypeptide, consisting of the amino acid sequence of any one of SEQ ID NOS: 42 to 47, and SEQ ID NO: 56.
2. The isolated or purified therapeutically effective hPCSK9 polypeptide consisting of the amino acid sequence of any one of SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 47, SEQ ID NO: 56 or combinations thereof.
3. The isolated or purified therapeutically effective hPCSK9 polypeptides of claim 2 , consisting of the combination of the amino acid sequence SEQ ID NO: 36 and SEQ ID NO: 42 or SEQ ID NO: 36 and SEQ ID NO: 47.
4. An isolated or purified therapeutically effective hPCSK9 polypeptide consisting of the amino acid sequence of SEQ ID NO: 56:
5. A pharmaceutical composition comprising a therapeutically effective amount of an isolated or purified therapeutically effective hPCSK9 polypeptide of claim 2 , and a pharmaceutically acceptable carrier.
6. A method of preventing or treating hypercholesterolemia comprising administering to a subject in need thereof at least one of an isolated or purified therapeutically effective hPCSK9 polypeptide of claim 2 , or combinations thereof.
7. The method of claim 6 , further comprising administering a HMG-CoA reductase inhibitors (statin).
8. A kit for use for the prevention or the treatment of hypercholesterolemia in a subject in need thereof, the kit comprising:
an isolated or purified therapeutically effective hPCSK9 polypeptide consisting of the amino acid sequence of any one of SEQ ID NOs 42 to 47, and SEQ ID NO:56 and
instructions on how to use the kit.
9. The kit of claim 8 , wherein the isolated or purified therapeutically effective hPCSK9 polypeptide is consisting of the amino acid sequence of any one of SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 47, SEQ ID NO: 56 or combinations thereof.
10. The kit of claim 9 , wherein the isolated or purified therapeutically effective hPCSK9 polypeptides is consisting of the combination of the amino acid sequence SEQ ID NO: 36 and SEQ ID NO: 42 or SEQ ID NO: 36 and SEQ ID NO: 47.
11. The kit of claim 8 , comprising
an isolated or purified therapeutically effective hPCSK9 polypeptide consisting the amino acid sequence:
12. The kit of claim 8 , further comprising a HMG-CoA reductase inhibitors (statin).
13. A pharmaceutical composition comprising a therapeutically effective amount of an isolated or purified therapeutically effective hPCSK9 polypeptide of claim 4 , and a pharmaceutically acceptable carrier.